Mohamed J Saadh, Faris Anad Muhammad, Rafid Jihad Albadr, Ashok Kumar Bishoyi, Suhas Ballal, Lakshay Bareja, K Satyam Naidu, Jasur Rizaev, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Ali M Ali Al-Nuaimi
{"title":"用于检测心血管疾病的纳米粒子生物传感器。","authors":"Mohamed J Saadh, Faris Anad Muhammad, Rafid Jihad Albadr, Ashok Kumar Bishoyi, Suhas Ballal, Lakshay Bareja, K Satyam Naidu, Jasur Rizaev, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Ali M Ali Al-Nuaimi","doi":"10.1016/j.cca.2024.120094","DOIUrl":null,"url":null,"abstract":"<p><p>Early detection and management of cardiovascular diseases (CVDs) are crucial for patient survival and long-term health. CVD biomarkers such as cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), Galectin-3 (Gal-3), etc are released into the circulation following heart muscle injury, ie, acute myocardial infarction (AMI). Biosensor technology including the use of nanoparticles can be designed to target specific biomarkers associated with CVD, enabling early detection and more rapid intervention to decrease morbidity and mortality. To date, with the combination of developed nanoparticles, several optical and electrochemical-based biosensors have successfully been used detection of CVD biomarkers. Nanomaterials, when introduced as the modifiers of sensor surfaces like electrodes and gold chips, can result in the more comprehensive and more effective immobilization of capture molecules, ie, antibodies, aptamers and other ligands, due to their large surface area. In recent years, inorganic nanoparticles have regularly been used in the production of biosensors mostly due to their excellent response intensification, adaptable functionalization chemistry, shape control, good biocompatibility, and great stability. In this review, we discuss the application of different kinds of nanoparticles for the sensitive and specific detection of CVD biomarkers.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120094"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nanoparticle biosensors for cardiovascular disease detection.\",\"authors\":\"Mohamed J Saadh, Faris Anad Muhammad, Rafid Jihad Albadr, Ashok Kumar Bishoyi, Suhas Ballal, Lakshay Bareja, K Satyam Naidu, Jasur Rizaev, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Ali M Ali Al-Nuaimi\",\"doi\":\"10.1016/j.cca.2024.120094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Early detection and management of cardiovascular diseases (CVDs) are crucial for patient survival and long-term health. CVD biomarkers such as cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), Galectin-3 (Gal-3), etc are released into the circulation following heart muscle injury, ie, acute myocardial infarction (AMI). Biosensor technology including the use of nanoparticles can be designed to target specific biomarkers associated with CVD, enabling early detection and more rapid intervention to decrease morbidity and mortality. To date, with the combination of developed nanoparticles, several optical and electrochemical-based biosensors have successfully been used detection of CVD biomarkers. Nanomaterials, when introduced as the modifiers of sensor surfaces like electrodes and gold chips, can result in the more comprehensive and more effective immobilization of capture molecules, ie, antibodies, aptamers and other ligands, due to their large surface area. In recent years, inorganic nanoparticles have regularly been used in the production of biosensors mostly due to their excellent response intensification, adaptable functionalization chemistry, shape control, good biocompatibility, and great stability. In this review, we discuss the application of different kinds of nanoparticles for the sensitive and specific detection of CVD biomarkers.</p>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\" \",\"pages\":\"120094\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cca.2024.120094\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2024.120094","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
心血管疾病(cvd)的早期发现和管理对患者的生存和长期健康至关重要。心血管疾病的生物标志物如心肌肌钙蛋白- i (cTnI)、n端前脑利钠肽(NT-proBNP)、肌酸激酶MB (CK-MB)、半乳糖凝集素-3 (Gal-3)等在心肌损伤即急性心肌梗死(AMI)后释放到循环中。包括使用纳米颗粒在内的生物传感器技术可以设计成针对与心血管疾病相关的特定生物标志物,从而实现早期检测和更快速的干预,以降低发病率和死亡率。到目前为止,随着纳米颗粒的结合,一些基于光学和电化学的生物传感器已经成功地用于CVD生物标志物的检测。纳米材料作为电极和金芯片等传感器表面的修饰剂,由于其较大的表面积,可以更全面、更有效地固定捕获分子,即抗体、适体和其他配体。近年来,无机纳米颗粒由于其优异的响应强化、适应性强的功能化化学、形状控制、良好的生物相容性和良好的稳定性而被广泛应用于生物传感器的生产中。本文综述了不同类型纳米颗粒在心血管疾病生物标志物检测中的应用。
Nanoparticle biosensors for cardiovascular disease detection.
Early detection and management of cardiovascular diseases (CVDs) are crucial for patient survival and long-term health. CVD biomarkers such as cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), Galectin-3 (Gal-3), etc are released into the circulation following heart muscle injury, ie, acute myocardial infarction (AMI). Biosensor technology including the use of nanoparticles can be designed to target specific biomarkers associated with CVD, enabling early detection and more rapid intervention to decrease morbidity and mortality. To date, with the combination of developed nanoparticles, several optical and electrochemical-based biosensors have successfully been used detection of CVD biomarkers. Nanomaterials, when introduced as the modifiers of sensor surfaces like electrodes and gold chips, can result in the more comprehensive and more effective immobilization of capture molecules, ie, antibodies, aptamers and other ligands, due to their large surface area. In recent years, inorganic nanoparticles have regularly been used in the production of biosensors mostly due to their excellent response intensification, adaptable functionalization chemistry, shape control, good biocompatibility, and great stability. In this review, we discuss the application of different kinds of nanoparticles for the sensitive and specific detection of CVD biomarkers.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.